<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04222127</url>
  </required_header>
  <id_info>
    <org_study_id>MD.19.03.157</org_study_id>
    <nct_id>NCT04222127</nct_id>
  </id_info>
  <brief_title>EUS-guided Obturation of High Risk Gastric Varices Versus Standard Endoscopic Treatment</brief_title>
  <official_title>EUS-Guided Cyanoacrylate Injection Versus Standard Endoscopic Technique in the Obturation of High Risk Gastric Varices</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mansoura University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mansoura University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Gastric varices occur in patients with portal hypertension, mostly secondary to liver&#xD;
      cirrhosis. Although they bleed less frequently than oesophageal varices, gastric variceal&#xD;
      bleeding tends to be more severe with reported higher mortality.&#xD;
&#xD;
      Endoscopic variceal obliteration (EVO) by direct endoscopic injection (DEI) using tissue&#xD;
      adhesives like glue, CYA or histoacryl demonstrated higher hemostasis and lower bleeding&#xD;
      rates compared to band ligation or sclerotherapy. Nevertheless, CYA treatment is known to be&#xD;
      associated with significant adverse events like para-variceal injection, hemorrhage from post&#xD;
      injection ulcer, needle sticking in the varix, intra-peritoneal injection leading to&#xD;
      peritonitis and adherence of the glue to the endoscope, fever, embolization into the renal&#xD;
      vein, IVC, pulmonary or systemic vessels.&#xD;
&#xD;
      Endoscopic ultrasound (EUS) offers unique access to abdominal arterial and venous&#xD;
      vasculature. This has had the most clinical impact on the treatment of gastroesophageal&#xD;
      varices, where EUS may play a role both in the management and can deliver therapy in the form&#xD;
      of glue injection, endovascular coil placement or a combination of the two. EUS enables an&#xD;
      assessment using Doppler to confirm vessel obliteration after treatment. However, targeting&#xD;
      the perforating feeder vessel rather than the varix lumen itself may theoretically minimize&#xD;
      the amount of CYA needed to achieve obliteration of GVs and thereby reduce the risk of&#xD;
      embolization.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-centre, pilot randomized trial study that includes 42 patients with gastric&#xD;
      varices that will be classified according to the Sarin and Kumar classification into GOV II&#xD;
      or IGV I with recently bleeding GV &amp; high-risk GV (defined by Baveno VI consensus for primary&#xD;
      prophylaxis).&#xD;
&#xD;
      Eligible patients will be randomized in 2 groups using computer-generated random number&#xD;
      sequences using excel software in concealed envelopes with block randomization design. Group&#xD;
      I will undergo EUS-guided CYA injection at entrance of perforator veins. Group II will&#xD;
      undergo DEI of CYA.&#xD;
&#xD;
      Each patient will be subjected to :&#xD;
&#xD;
        -  Written informed consent will be obtained from each patient, including a discussion on&#xD;
           the procedure.&#xD;
&#xD;
        -  Clinical assessment including history taking and physical examination&#xD;
&#xD;
        -  Routine laboratory investigations including complete blood picture and serum creatinine.&#xD;
&#xD;
        -  Liver function profile (serum bilirubin, AST, ALT , albumin and prothrombin time).&#xD;
&#xD;
        -  The severity of underlying disease will be assessed by the Child-Turcotte-Pugh score&#xD;
           (CTP) based on serum albumin, bilirubin, prothrombin time, the presence of ascites and&#xD;
           encephalopathy.&#xD;
&#xD;
        -  All procedures will be performed under deep sedation or general anesthesia in the left&#xD;
           lateral position.&#xD;
&#xD;
        -  Intravenous antibiotics will be administered to all patients prior to the endoscopic&#xD;
           procedure to minimize the risk of secondary bacterial infection. Oral or intravenous&#xD;
           antibiotics will be continued for at least 3 days following variceal injection.&#xD;
&#xD;
             -  Endoscopic procedure and technique:&#xD;
&#xD;
        -  Standard diagnostic upper endoscopy will be performed in order to classify the varices&#xD;
           according to the classification of Sarin and Kumar. Only high risk GOV II and IGV I&#xD;
           varices (&gt;10 mm) will be included.&#xD;
&#xD;
        -  EUS examination will be done in all patients with a Pentax linear Echoendoscope&#xD;
           EG3870UTK (PENTAX medical, Tokyo, Japan) attached to a Hitachi Avius ultrasound system&#xD;
           (Hitachi Medical Systems, Tokyo, Japan). All EUS examinations will be done by two&#xD;
           endosonographers. The echoendoscope will be positioned in the distal esophagus at the&#xD;
           level of the cardia to visualize the gastric fundus and intramural varices.&#xD;
&#xD;
        -  EUS will be used to display the vascular anatomy, in particular the feeding vein. GVs&#xD;
           will be classified endosonographically according to Boustière et al which considered&#xD;
           size of GVs and gastric wall abnormalities :&#xD;
&#xD;
           1: Size of GVs:&#xD;
&#xD;
        -  Grade 0 (none)&#xD;
&#xD;
        -  Grade 1 (small or non-confluent varies &lt; 5 mm)&#xD;
&#xD;
        -  Grade 2 (large or confluent varices ≥ 5 mm) 2: Abnormalities of gastric wall:&#xD;
&#xD;
             1. Grade 0 (none)&#xD;
&#xD;
             2. Grade 1 (thickening and brilliance of the third hyperechogenic layer with or&#xD;
                without fine internal anechogenic structures).&#xD;
&#xD;
             3. Grade 2 (visible vessels in the third layer which deform the entire wall, with&#xD;
                penetrating varices).&#xD;
&#xD;
        -  EUS-guided injection of CYA will be done at entrance of of the varix or the perforator&#xD;
           veins when identifiable using a mixture (1:1) of 2-octyl-cyanoacrylate &amp; lipidol using&#xD;
           19G EUS-FNA needle in Group I, or DEI of CYA in Group II.&#xD;
&#xD;
             -  Follow-up after endoscopy:&#xD;
&#xD;
      After the procedure, patients will be observed for 2 hours in the recovery room before being&#xD;
      discharged. Endoscopic examination and Doppler EUS will be repeated in all patients at 3, and&#xD;
      6 months post-procedure (or sooner with recurrent bleeding) to confirm eradication.&#xD;
      Hemostasis, early post treatment bleeding and late post treatment bleeding will be recorded&#xD;
      according to Baveno VI concensus.&#xD;
&#xD;
      GVs will be considered obliterated by direct endoscopy when not visible and/or hardened to&#xD;
      catheter palpation. Obliteration by Doppler EUS will be considered by visualization of clot&#xD;
      and absence of Doppler flow within the gastric wall. Repeat injection will be performed in&#xD;
      the absence of obliteration. Direct endoscopic and Doppler EUS examinations will be repeated&#xD;
      again at 3, and 6 months after each injection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment emergent adverse events &amp; oblitration rate</measure>
    <time_frame>6 months</time_frame>
    <description>measure the technical success rate defined as complete variceal obliteration and complications rate including bleeding, pulmonary embolism (PE), ulcers, fever, paravariceal injection &amp; rebleeding.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amount of glue used</measure>
    <time_frame>6 months</time_frame>
    <description>amount of cyanoacrylate used to complete obliteration in ml.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of sessions</measure>
    <time_frame>6 months</time_frame>
    <description>calculate the number of sessions needed to achieve oblitration of gastric varices</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Gastric Varix</condition>
  <arm_group>
    <arm_group_label>EUS-guided injection of CYA of GVs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EUS-guided injection of CYA will be done at entrance of of the varix or the perforator veins when identifiable using a mixture (1:1) of 2-octyl-cyanoacrylate &amp; lipidol using 19G EUS-FNA needle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Direct endoscopic injection of CYA of GVs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Direct endoscopic injection of CYA of the gastric varix using standard endoscopy</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>EUS guided injection of gastric varices by CYA</intervention_name>
    <description>EUS-guided injection of CYA will be done at entrance of of the varix or the perforator veins when identifiable using a mixture (1:1) of 2-octyl-cyanoacrylate &amp; lipidol using 19G EUS-FNA needle</description>
    <arm_group_label>EUS-guided injection of CYA of GVs</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Direct endoscopic injection of gastric varices by CYA</intervention_name>
    <description>Direct endoscopic injection of gastric varix by CYA</description>
    <arm_group_label>Direct endoscopic injection of CYA of GVs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  High risk GOV II and IGV I varices (&gt;10 mm) on initial standard diagnostic upper&#xD;
             endoscopy&#xD;
&#xD;
          -  Recent bleeding and primary prophylaxis&#xD;
&#xD;
          -  Patients who are unable or unwilling to undergo alternative therapies for GV [such as&#xD;
             transjugular intrahepatic portosystemic shunts (TIPS) or surgery], or prior TIPS had&#xD;
             failed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Inability to give informed consent for the procedure.&#xD;
&#xD;
          -  Concurrent hepatorenal syndrome and/or multiorgan failure.&#xD;
&#xD;
          -  Presence of HCC &amp;/or portal vein thrombosis.&#xD;
&#xD;
          -  Previous endoscopic treatment for GVs.&#xD;
&#xD;
          -  Platelet count less than 50,000/ml or International Normalized Rate (INR) &gt;2&#xD;
&#xD;
          -  Esophageal stricture&#xD;
&#xD;
          -  Previous esophageal or gastric surgery.&#xD;
&#xD;
          -  Pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fady S Karam, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ahmed Y Altonbary, MD</last_name>
    <role>Study Director</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hazim H Almenshawy, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ayman A Aldosoky, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seham M Seif, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Mansoura University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fady S Karam, Master</last_name>
    <phone>+201028838396</phone>
    <email>fady-sabry40@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ahmed Y Altonbary</last_name>
    <phone>01005100091</phone>
    <email>Altonbary@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Specialized Medical hospital</name>
      <address>
        <city>Mansoura</city>
        <state>Dakahlia</state>
        <zip>+2050</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fady S Karam, Master</last_name>
      <phone>+201028838396</phone>
      <email>fady_sabry40@yahoo.com</email>
    </contact>
    <investigator>
      <last_name>Ahmed Y Altonbary, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Hazim H Almenshawy, Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ayman A Aldesoky, Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Seham M Seif, Professor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <reference>
    <citation>Romero-Castro R, Pellicer-Bautista FJ, Jimenez-Saenz M, Marcos-Sanchez F, Caunedo-Alvarez A, Ortiz-Moyano C, Gomez-Parra M, Herrerias-Gutierrez JM. EUS-guided injection of cyanoacrylate in perforating feeding veins in gastric varices: results in 5 cases. Gastrointest Endosc. 2007 Aug;66(2):402-7.</citation>
    <PMID>17643723</PMID>
  </reference>
  <reference>
    <citation>Wang AJ, Li BM, Zheng XL, Shu X, Zhu X. Utility of endoscopic ultrasound in the diagnosis and management of esophagogastric varices. Endosc Ultrasound. 2016 Jul-Aug;5(4):218-24. doi: 10.4103/2303-9027.187840. Review.</citation>
    <PMID>27503152</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>October 5, 2019</study_first_submitted>
  <study_first_submitted_qc>January 6, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 9, 2020</study_first_posted>
  <last_update_submitted>January 6, 2020</last_update_submitted>
  <last_update_submitted_qc>January 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gastric Varices</keyword>
  <keyword>EUS</keyword>
  <keyword>Cyanoacrylate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal and Gastric Varices</mesh_term>
    <mesh_term>Varicose Veins</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>January 1, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/27/NCT04222127/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

